De A, Duseja A. Nonalcoholic fatty liver disease: Indian perspective. Clin Liver Dis (Hoboken). 2021;18:158–63. https://doi.org/10.1002/cld.1141.

Article  PubMed  PubMed Central  Google Scholar 

Anton MC, Shanthi B, Sridevi C. Prevalence of non-alcoholic fatty liver disease in urban adult population in a tertiary care center, Chennai. Indian J Community Med. 2023;48:601–4. https://doi.org/10.4103/ijcm.ijcm_437_22.

Article  PubMed  Google Scholar 

Kir S, Kliewer SA, Mangelsdorf DJ. Roles of FGF19 in liver metabolism. Cold Spring Harb Symp Quant Biol. 2011;76:139–44. https://doi.org/10.1101/sqb.2011.76.010710.

Article  CAS  PubMed  Google Scholar 

Liu Y, Cao M, Cai Y, Li X, Zhao C, Cui R. Dissecting the role of the FGF19-FGFR4 signaling pathway in cancer development and progression. Front Cell Dev Biol. 2020;8:95. https://doi.org/10.3389/fcell.2020.00095.

Lutz SZ, Hennige AM, Peter A, et al. The Gly385 (388) Arg polymorphism of the FGFR4 receptor regulates hepatic lipogenesis under healthy diet. J Clin Endocrinol Metab. 2019;104:2041–53. https://doi.org/10.1210/jc.2018-01573.

Article  PubMed  Google Scholar 

Han H, Jiang Y, Wang M, et al. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis. Crit Rev Food Sci Nutr. 2023;63:1689–06. https://doi.org/10.1080/10408398.2021.1966738.

Article  CAS  PubMed  Google Scholar 

Harte AL, da Silva NF, Creely SJ, et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond). 2010;7:15. https://doi.org/10.1186/1476-9255-7-15.

Miura K, Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:7381–91. https://doi.org/10.3748/wjg.v20.i23.7381.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mohan P, Sundar V, Bhaskar E, Anthony S. Estimation of upper limit of normal for serum alanine transaminase in healthy South Indian population. Indian J Clin Biochem. 2017;32:337–42. https://doi.org/10.1007/s12291-016-0616-3.

Article  CAS  PubMed  Google Scholar 

Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23:8263–76. https://doi.org/10.3748/wjg.v23.i47.8263.

Article  PubMed  PubMed Central  Google Scholar 

Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739–52. https://doi.org/10.1016/S2468-1253(20)30077-7.

Article  PubMed  Google Scholar 

Amarapurkar D, Kamani P, Patel N,  et al. Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol. 2007;6:161–3.

Article  PubMed  Google Scholar 

Singh SP, Nayak S, Swain M, et al. Prevalence of nonalcoholic fatty liver disease in coastal eastern India: a preliminary ultrasonographic survey. Trop Gastroenterol. 2004;25:76–9.

PubMed  Google Scholar 

Akdeniz Odemis D, Tuncer SB, Adamnejad Ghafour A, et al. FGFR4 c.1162G > A (p.Gly388Arg) Polymorphism analysis in Turkish patients with retinoblastoma. J Oncol. 2020;2020:9401038.

Bange J, Prechtl D, Cheburkin Y, et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg388 allele. Can Res. 2002;62:840–7.

CAS  Google Scholar 

Schreuder TC, Marsman HA, Lenicek M, et al. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol. 2010;298:G440–5. https://doi.org/10.1152/ajpgi.00322.2009.

Yang MN, Huang R, Liu X, et al. Fibroblast growth factor 19 in gestational diabetes mellitus and fetal growth. Front Endocrinol (Lausanne). 2022;12:805722. https://doi.org/10.3389/fendo.2021.805722.

Article  Google Scholar 

Anderson KM, Gayer CP. The pathophysiology of farnesoid X receptor (FXR) in the GI tract: inflammation, barrier function and innate immunity. Cells. 2021;10:3206.  https://doi.org/10.3390/cells10113206.

Article  PubMed  PubMed Central  Google Scholar 

Horikawa T, Oshima T, Li M,  et al. Chenodeoxycholic acid releases pro-inflammatory cytokines from small intestinal epithelial cells through the farnesoid X receptor. Gastroenterologia. 1963;100:286–94.

Article  Google Scholar 

Meli R, Mattace Raso G, Calignano A. Role of innate immune response in non-alcoholic fatty liver disease: metabolic complications and therapeutic tools. Front Immunol. 2014;5:177.

Google Scholar 

Huang C, Zhou Y, Cheng J, et al. Pattern recognition receptors in the development of nonalcoholic fatty liver disease and progression to hepatocellular carcinoma: an emerging therapeutic strategy.  Front Endocrinol (Lausanne). 2023;14:1145392. https://doi.org/10.3389/fendo.2023.1145392.

Article  Google Scholar 

Kessoku T, Kobayashi T, Imajo K, et al. Endotoxins and non-alcoholic fatty liver disease. Front Endocrinol (Lausanne). 2021;12:770986. https://doi.org/10.3389/fendo.2021.770986.

Darmadi D, Riska R. Association between serum interleukin (IL)-12 level and severity of non-alcoholic fatty liver disease (NAFLD). Rom J Intern Med. 2021;59:66–72. https://doi.org/10.2478/rjim-2020-0029.

Article  PubMed  Google Scholar 

Auguet T, Bertran L, Binetti J, et al. Relationship between IL-8 circulating levels and TLR2 hepatic expression in women with morbid obesity and nonalcoholic steatohepatitis.  Int J Mol Sci. 2020;21:4189.  https://doi.org/10.3390/ijms21114189.

Article  PubMed  PubMed Central  Google Scholar 

Zhang LJ, Wang XZ. Interleukin-10 and chronic liver disease. World J Gastroenterol. 2006;12:1681–5. https://doi.org/10.3748/wjg.v12.i11.1681.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kesar V, Odin JA. Toll-like receptors and liver disease. Liver Int. 2014;34:184–96. https://doi.org/10.1111/liv.12315.

Article  CAS  PubMed  Google Scholar 

Gao L, Lang L, Zhao X, et al. FGF19 amplification reveals an oncogenic dependency upon autocrine FGF19/FGFR4 signaling in head and neck squamous cell carcinoma. Oncogene. 2019;38:2394–404. https://doi.org/10.1038/s41388-018-0591-7.

Article  CAS  PubMed  Google Scholar 

Harrison SA, Abdelmalek MF, Neff G,  et al. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2022;7:603–16.

Article  PubMed  Google Scholar 

Harrison SA, Neff G, Guy CD,  et al. Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis. Gastroenterology. 2021;160:219–31.

Article  CAS  PubMed  Google Scholar 

Harrison SA, Rossi SJ, Paredes AH,  et al. NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis. Hepatology. 2020;71:1198–212.

Article  CAS  PubMed  Google Scholar 

Tian H, Zhang S, Liu Y, Wu Y, Zhang D. Fibroblast growth factors for nonalcoholic fatty liver disease: opportunities and challenges. Int J Mol Sci. 2023;24:4583. https://doi.org/10.3390/ijms24054583.